Read + Share
Amedeo Smart
Independent Medical Education
Tang X, Hu J, Guo R, Wang Y, et al. RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs. Cancer Lett 2025;612:217455.PMID: 39800214
Email
LinkedIn
Privacy Policy